← BioCryst Pharmaceuticals overview

BioCryst Pharmaceuticals vs Alnylam Pharmaceuticals: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

BioCryst Pharmaceuticals Inc (BCRX)

Q3 2026
▲3

BioCryst Swings to Profit, Raises Guidance, Expands ORLADEYO

  • Raised 2026 revenue guidance and first profit BioCryst lifted full-year revenue guidance to $690–715 million and cut cost guidance, after Q2 revenue jumped 34% to $218 million and the company posted its first profit. More sales and lower costs mean more cash, which supports a higher stock price.

    This is the core new financial event that directly improves earnings and investor confidence.

  • ORLADEYO pediatric expansion in US and Japan Japan approved ORLADEYO for children aged 2–12, the first oral preventive there, and US pellet shipments began with 47 quick prescriptions. A wider label means more patients and future sales, pushing the stock up.

    New regulatory approval and real pediatric uptake expand the market for the main revenue drug.

  • Takeover speculation on first profitable year Analysts see Takeda as a likely buyer because its HAE drug Takhzyro is threatened by BioCryst's navenibart, with AstraZeneca also named. No talks are confirmed, but the buzz can lift the shares as investors bet on a deal.

    New speculation about a buyout adds a potential premium to the stock price.

  • Closing internal discovery, shifting to external deals BioCryst is closing its Birmingham research site and ending internal discovery to cut costs and buy rare-disease assets instead. This saves money now but reduces long-term self-generated innovation, and the company still has negative equity and $822 million in debt.

    This strategic shift and the debt load are the main counterweights to the positive profit and guidance news.

August 2026
▲3

BioCryst Swings to Profit, Raises Guidance, Expands ORLADEYO

  • Raised 2026 revenue guidance and first profit BioCryst lifted full-year revenue guidance to $690–715 million and cut cost guidance, after Q2 revenue jumped 34% to $218 million and the company posted its first profit. More sales and lower costs mean more cash, which supports a higher stock price.

    This is the core new financial event that directly improves earnings and investor confidence.

  • ORLADEYO pediatric expansion in US and Japan Japan approved ORLADEYO for children aged 2–12, the first oral preventive there, and US pellet shipments began with 47 quick prescriptions. A wider label means more patients and future sales, pushing the stock up.

    New regulatory approval and real pediatric uptake expand the market for the main revenue drug.

  • Takeover speculation on first profitable year Analysts see Takeda as a likely buyer because its HAE drug Takhzyro is threatened by BioCryst's navenibart, with AstraZeneca also named. No talks are confirmed, but the buzz can lift the shares as investors bet on a deal.

    New speculation about a buyout adds a potential premium to the stock price.

  • Closing internal discovery, shifting to external deals BioCryst is closing its Birmingham research site and ending internal discovery to cut costs and buy rare-disease assets instead. This saves money now but reduces long-term self-generated innovation, and the company still has negative equity and $822 million in debt.

    This strategic shift and the debt load are the main counterweights to the positive profit and guidance news.

Latest
▲3

BioCryst Swings to Profit, Raises Guidance, Expands ORLADEYO

  • Raised 2026 revenue guidance and first profit BioCryst lifted full-year revenue guidance to $690–715 million and cut cost guidance, after Q2 revenue jumped 34% to $218 million and the company posted its first profit. More sales and lower costs mean more cash, which supports a higher stock price.

    This is the core new financial event that directly improves earnings and investor confidence.

  • ORLADEYO pediatric expansion in US and Japan Japan approved ORLADEYO for children aged 2–12, the first oral preventive there, and US pellet shipments began with 47 quick prescriptions. A wider label means more patients and future sales, pushing the stock up.

    New regulatory approval and real pediatric uptake expand the market for the main revenue drug.

  • Takeover speculation on first profitable year Analysts see Takeda as a likely buyer because its HAE drug Takhzyro is threatened by BioCryst's navenibart, with AstraZeneca also named. No talks are confirmed, but the buzz can lift the shares as investors bet on a deal.

    New speculation about a buyout adds a potential premium to the stock price.

  • Closing internal discovery, shifting to external deals BioCryst is closing its Birmingham research site and ending internal discovery to cut costs and buy rare-disease assets instead. This saves money now but reduces long-term self-generated innovation, and the company still has negative equity and $822 million in debt.

    This strategic shift and the debt load are the main counterweights to the positive profit and guidance news.

Alnylam Pharmaceuticals Inc (ALNY)

Q3 2026
▲2▼2

Alnylam's TTR Guidance Cut Triggers 29% Plunge Despite Record Quarter

  • TTR Guidance Cut Sends Shares Down 29% Alnylam lowered its 2026 TTR revenue guidance to $4.2–4.5 billion from $4.4–4.7 billion, citing slower second-line demand for Amvuttra. The stock plunged 29% as investors feared the flagship franchise's growth is decelerating, overshadowing strong Q2 results.

    This is the single biggest new event of the period and the main reason ALNY is moving right now.

  • Amvuttra Tops $1 Billion in a Quarter for First Time Amvuttra exceeded $1 billion in quarterly sales, with total product revenue up 74% and non-GAAP operating income tripling to $318 million. This shows the drug is still growing strongly, but the guidance cut signals the pace will slow.

    It is the key new financial result that contrasts with the guidance cut and explains the mixed market reaction.

  • Rival ATTR-CM Drug Fails, Boosting Alnylam's Competitive Edge AstraZeneca and Ionis's Wainua failed a Phase 3 ATTR-CM trial, removing a potential competitor. Alnylam shares initially rose 18% as its Amvuttra faces less competition in the cardiomyopathy market, though the later guidance cut reversed those gains.

    This is a major new competitive development that initially drove the stock up and remains a positive force.

  • Securities Fraud Investigation Adds Legal Uncertainty Kirby McInerney launched an investigation into potential securities law violations following the guidance cut. While no lawsuit has been filed, the probe adds uncertainty and could pressure the stock as investors weigh legal risks.

    It is a new negative development that could affect investor sentiment and is directly tied to the guidance cut.

July 2026
▲2▼2

Alnylam's TTR Guidance Cut Triggers 29% Plunge Despite Record Quarter

  • TTR Guidance Cut Sends Shares Down 29% Alnylam lowered its 2026 TTR revenue guidance to $4.2–4.5 billion from $4.4–4.7 billion, citing slower second-line demand for Amvuttra. The stock plunged 29% as investors feared the flagship franchise's growth is decelerating, overshadowing strong Q2 results.

    This is the single biggest new event of the period and the main reason ALNY is moving right now.

  • Amvuttra Tops $1 Billion in a Quarter for First Time Amvuttra exceeded $1 billion in quarterly sales, with total product revenue up 74% and non-GAAP operating income tripling to $318 million. This shows the drug is still growing strongly, but the guidance cut signals the pace will slow.

    It is the key new financial result that contrasts with the guidance cut and explains the mixed market reaction.

  • Rival ATTR-CM Drug Fails, Boosting Alnylam's Competitive Edge AstraZeneca and Ionis's Wainua failed a Phase 3 ATTR-CM trial, removing a potential competitor. Alnylam shares initially rose 18% as its Amvuttra faces less competition in the cardiomyopathy market, though the later guidance cut reversed those gains.

    This is a major new competitive development that initially drove the stock up and remains a positive force.

  • Securities Fraud Investigation Adds Legal Uncertainty Kirby McInerney launched an investigation into potential securities law violations following the guidance cut. While no lawsuit has been filed, the probe adds uncertainty and could pressure the stock as investors weigh legal risks.

    It is a new negative development that could affect investor sentiment and is directly tied to the guidance cut.

Latest
▲2▼2

Alnylam's TTR Guidance Cut Triggers 29% Plunge Despite Record Quarter

  • TTR Guidance Cut Sends Shares Down 29% Alnylam lowered its 2026 TTR revenue guidance to $4.2–4.5 billion from $4.4–4.7 billion, citing slower second-line demand for Amvuttra. The stock plunged 29% as investors feared the flagship franchise's growth is decelerating, overshadowing strong Q2 results.

    This is the single biggest new event of the period and the main reason ALNY is moving right now.

  • Amvuttra Tops $1 Billion in a Quarter for First Time Amvuttra exceeded $1 billion in quarterly sales, with total product revenue up 74% and non-GAAP operating income tripling to $318 million. This shows the drug is still growing strongly, but the guidance cut signals the pace will slow.

    It is the key new financial result that contrasts with the guidance cut and explains the mixed market reaction.

  • Rival ATTR-CM Drug Fails, Boosting Alnylam's Competitive Edge AstraZeneca and Ionis's Wainua failed a Phase 3 ATTR-CM trial, removing a potential competitor. Alnylam shares initially rose 18% as its Amvuttra faces less competition in the cardiomyopathy market, though the later guidance cut reversed those gains.

    This is a major new competitive development that initially drove the stock up and remains a positive force.

  • Securities Fraud Investigation Adds Legal Uncertainty Kirby McInerney launched an investigation into potential securities law violations following the guidance cut. While no lawsuit has been filed, the probe adds uncertainty and could pressure the stock as investors weigh legal risks.

    It is a new negative development that could affect investor sentiment and is directly tied to the guidance cut.

Q2 2026
▲4

Alnylam's RNAi Engine Roars: AI Deals, Regulatory Wins, and a 121% Revenue Surge

  • Amvuttra's 187% sales jump powers 121% total revenue growth Amvuttra sales soared 187% to $889.9 million, driving total Q1 product revenue up 121% to $1.04 billion. This blockbuster growth is the core reason Alnylam's stock can rebound, as it proves the company's flagship drug is winning in the cardiomyopathy market.

    This is the fundamental growth engine behind the stock's potential recovery and analyst optimism.

  • AI partnerships with Inceptive and Komodo aim to speed drug discovery and commercialization Alnylam formed a $2 billion AI collaboration with Inceptive Nucleics to accelerate RNAi drug discovery and expanded its Komodo Health partnership to scale AI analytics. These deals could shorten development timelines and boost pipeline productivity, supporting long-term growth.

    These new AI initiatives signal future pipeline expansion and operational efficiency, key for a biotech's valuation.

  • Cemdisiran accepted for FDA and EMA review in myasthenia gravis Regulators accepted marketing applications for cemdisiran, with FDA priority review and a November decision date. This milestone brings a potential new rare-disease therapy closer to market, diversifying revenue beyond Amvuttra and adding a near-term catalyst.

    A regulatory acceptance is a concrete step toward a new product approval, directly impacting future revenue.

  • Analysts see 45% upside as Brown Advisory initiates a position Wall Street's average price target is $436, about 45% above the recent close, and Brown Advisory initiated a stake citing an attractive entry point. These votes of confidence suggest the market may be undervaluing Alnylam's growth prospects.

    Institutional buying and analyst targets reflect external validation of the company's value after a steep selloff.

June 2026
▲4

Alnylam's RNAi Engine Roars: AI Deals, Regulatory Wins, and a 121% Revenue Surge

  • Amvuttra's 187% sales jump powers 121% total revenue growth Amvuttra sales soared 187% to $889.9 million, driving total Q1 product revenue up 121% to $1.04 billion. This blockbuster growth is the core reason Alnylam's stock can rebound, as it proves the company's flagship drug is winning in the cardiomyopathy market.

    This is the fundamental growth engine behind the stock's potential recovery and analyst optimism.

  • AI partnerships with Inceptive and Komodo aim to speed drug discovery and commercialization Alnylam formed a $2 billion AI collaboration with Inceptive Nucleics to accelerate RNAi drug discovery and expanded its Komodo Health partnership to scale AI analytics. These deals could shorten development timelines and boost pipeline productivity, supporting long-term growth.

    These new AI initiatives signal future pipeline expansion and operational efficiency, key for a biotech's valuation.

  • Cemdisiran accepted for FDA and EMA review in myasthenia gravis Regulators accepted marketing applications for cemdisiran, with FDA priority review and a November decision date. This milestone brings a potential new rare-disease therapy closer to market, diversifying revenue beyond Amvuttra and adding a near-term catalyst.

    A regulatory acceptance is a concrete step toward a new product approval, directly impacting future revenue.

  • Analysts see 45% upside as Brown Advisory initiates a position Wall Street's average price target is $436, about 45% above the recent close, and Brown Advisory initiated a stake citing an attractive entry point. These votes of confidence suggest the market may be undervaluing Alnylam's growth prospects.

    Institutional buying and analyst targets reflect external validation of the company's value after a steep selloff.

▲4

Alnylam's RNAi Engine Roars: AI Deals, Regulatory Wins, and a 121% Revenue Surge

  • Amvuttra's 187% sales jump powers 121% total revenue growth Amvuttra sales soared 187% to $889.9 million, driving total Q1 product revenue up 121% to $1.04 billion. This blockbuster growth is the core reason Alnylam's stock can rebound, as it proves the company's flagship drug is winning in the cardiomyopathy market.

    This is the fundamental growth engine behind the stock's potential recovery and analyst optimism.

  • AI partnerships with Inceptive and Komodo aim to speed drug discovery and commercialization Alnylam formed a $2 billion AI collaboration with Inceptive Nucleics to accelerate RNAi drug discovery and expanded its Komodo Health partnership to scale AI analytics. These deals could shorten development timelines and boost pipeline productivity, supporting long-term growth.

    These new AI initiatives signal future pipeline expansion and operational efficiency, key for a biotech's valuation.

  • Cemdisiran accepted for FDA and EMA review in myasthenia gravis Regulators accepted marketing applications for cemdisiran, with FDA priority review and a November decision date. This milestone brings a potential new rare-disease therapy closer to market, diversifying revenue beyond Amvuttra and adding a near-term catalyst.

    A regulatory acceptance is a concrete step toward a new product approval, directly impacting future revenue.

  • Analysts see 45% upside as Brown Advisory initiates a position Wall Street's average price target is $436, about 45% above the recent close, and Brown Advisory initiated a stake citing an attractive entry point. These votes of confidence suggest the market may be undervaluing Alnylam's growth prospects.

    Institutional buying and analyst targets reflect external validation of the company's value after a steep selloff.

© 2026 MarketIVWhy